Males and females differ in response to opioid agonist medications

American Journal on Addictions

Volumn 14, Issue 3, 2005, Pages 223-233

  Jones, Hendrée E ^a,b   Fitzgerald, Heather ^a   Johnson, Rolley E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; LEVACETYLMETHADOL; METHADONE; OPIATE; OPIATE AGONIST;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; DRUG USE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ADULT; BUPRENORPHINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHADONE; METHADYL ACETATE; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; SEX FACTORS; TREATMENT OUTCOME;

EID: 22144493856     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490590949569     Document Type: Article

References (47)

1. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50:222-239.
2. Petitjean S, Stoler R, Déglon J-J, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 2001;62:97-104.
3. Perez de los Cobos J, Martin S, Etcheberrigaray A, et al. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend. 2000;59:223-233.
4. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60:39-50.
5. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343:1290-1297.
6. Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry. 2000;47:1072-1079.
7. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000-1005.
8. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Useful predictor of outcome in methadone-treated patients: results from a controlled clinical trial with three doses of methadone. J Maintenance Addict. 1998;1:15-28.
9. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;A93:475-486.
10. Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in buprenorphine-versus methadone-maintained patients. J Nerv Ment Dis. 1998;186:35-43.
11. Jones HE, Strain EC, Bigelow GE, et al. Induction with levomethadyl acetate: safety and efficacy. Arch Gen Psychiatry. 1998;55:729-736.
12. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997; 54:713-720.
13. Eissenberg T, Bigelow GE, Strain EC, et al. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: a randomized clinical trial. JAMA. 1997;277:1945-1951.
14. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53:401-407.
15. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend. 1995;40:27-35.
16. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1025-1030.
17. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychophamacol. 1996;16:58-67.
18. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993;119:23-27.
19. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis. 1993;181:358-364.
20. Ling W, Klett CJ, Gillis RD. A cooperative clinical study of methadyl acetate: I. three-times-a-week regimen. Arch Gen Psychiatry. 1978;35:345-353.
21. Ling W, Dorus W, Hargreaves WA, Resnick R, Senay E, Tuason VB. Alternative induction and crossover schedules for methadyl acetate. Arch Gen Psychiatry. 1984;41:193-199.
22. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988;43:72-78.
23. Bickel WK, Amass L, Crean JP, Badger GJ. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl). 1999;146:111-118.
24. Freedman RR, Czertko G. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. Drug Alcohol Depend. 1981;8:215-222.
25. Senay EC, Dorus W, Renault PF. Methadyl acetate and methadone: an open comparison. JAMA. 1977;237:138-142.
26. Madden C, Singer G, Jagoda J, Jethwa J, Croxford R. Opiate-seeking behavior under conditions of methadone detoxification and removal. Int J Addict. 1986;21:947-953.
27. Judson BA, Goldstein A, Inturrisi CE. Methadyl acetate (LAAM) in the treatment of heroin addicts: II. double-blind comparison of gradual and abrupt detoxification. Arch Gen Psychiatry. 1983;40:834-840.
28. Sorensen JL, Hargreaves WA, Weinberg JA. Withdrawal from heroin in three or six weeks: comparison of methadyl acetate and methadone. Arch Gen Psychiatry. 1982;39:167-171.
29. Taylor JR, Watson ID, Tames FJ, Lowe D. Detection of drug use in a methadone maintenance clinic: sweat patches versus urine testing. Addiction. 1998;93:847-853.
30. Levin FR, Foltin RW, Fischman MW. Pattern of cocaine use in methadone-maintained individuals applying for research studies. J Addict Dis. 1996;15:97-106.
31. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-2755.
32. Ling W, Charuvastra C, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts: a veterans administration cooperative study. Arch Gen Psychiatry. 1976;33:709-720.
33. McLellan AT, Luborsky L, Cacciola J, et al. New data from the Addiction Severity Index: reliability and validity in three centers. J Nerv Ment Dis. 1985;173:412-423.
34. Keppel G. Design and Analysis: A Researcher's Handbook. Second edition. Englewood Cliffs, NJ: Prentice-Hall, Inc.; 1982.
35. Petty NM, Bickel WK. Gender differences in hostility of opioid-dependent outpatients: role in early treatment termination. Drug Alcohol Depend. 2000;58:27-33.
36. Karuntzos GT, Caddell JM, Dennis ML. Gender differences in vocational needs and outcomes for methadone treatment clients. J Psychoactive Drugs. 1994;26:173-180.
37. Hser YI, Anglin MD, Liu Y. A survival analysis of gender and ethnic differences in responsiveness to methadone maintenance treatment. Int J Addict. 1990-91;25:1295-1315.
38. Anglin MD, Hser YI, Booth MW. Sex differences in addict careers: 4. treatment. Am J Drug Alcohol Abuse. 1987;13:253-280.
39. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003; 98:673-684.
40. Cepeda MS, Carr DB. Women experience more pain and require more morphine than men to achieve a similar degree of analgesia. Anesth Analg. 2003;97:1464-1468.
41. Unruh AM. Gender variations in clinical pain experience. Pain. 1996;65:123-167.
42. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. J Gen Intern Med. 2001;16:266-275.
43. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry. 1999;156:842-848.
44. Zubieta JK, Smith YR, Bueller JA, et al. Mu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci. 2002;22:5100-5107.
45. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med. 1996;2:1248-1250.
46. Kreek MJ, Schluger J, Borg L, Gunduz M, Ho A. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pbarmacol Exp Ther. 1999;288:260-269.
47. Craft RM. Sex differences in opioid analgesia: "from mouse to man." Can J Pain. 2003;19: 175-186.